ECFS 2026: New Horizons in Cystic Fibrosis Treatment

As part of the 49th European Cystic Fibrosis Conference (ECFS 2026), held in Lisbon, Portugal, from June 3–6, 2026, the Ukrainian delegation participated in several key scientific sessions. The delegation included Larisa Voloshyna, President of the All-Ukrainian Association for Assistance to Patients with Cystic Fibrosis, physicians Yuliia Ostapyshena and Mariia Polishchuk, as well as Ms. Nataliia, Ms. Anna, and Ms. Bohdana.

Our representatives took part in highly informative scientific discussions, particularly in sessions dedicated to fungal lung infections, CFTR gene mutation carriers, and non-tuberculous mycobacteria. The knowledge gained provides new opportunities for improving the diagnosis and treatment of cystic fibrosis in Ukraine.

A message from Larisa Voloshyna:

The first session focused on fungal lung diseases. Researchers presented data showing the increasing resistance of Aspergillus species to antifungal medications, as well as new diagnostic approaches for detecting these infections. At the same time, encouraging results were shared demonstrating the positive impact of CFTR modulators in reducing fungal lung involvement among patients with cystic fibrosis.

The second session focused on CFTR gene mutation carriers. Current research indicates that carrying a single CFTR mutation does not mean a person has cystic fibrosis; however, some carriers may have an increased risk of developing certain respiratory and gastrointestinal conditions. Particular attention was given to the interaction between genetic and environmental factors that may influence the development and manifestation of diseases throughout a person’s lifetime.

The third session focused on Mycobacterium abscessus, one of the most challenging infections affecting people with cystic fibrosis. Advanced technologies, including single-cell sequencing and tissue analysis, are providing new insights into how the body responds to this infection and why the bacterium remains a colonizer in some patients while causing severe lung disease in others. These findings open promising opportunities for earlier diagnosis and more personalized treatment approaches.

All three sessions were united by one important message: the future of cystic fibrosis care lies not only in managing symptoms, but in a deep understanding of each patient’s individual characteristics, genetics, immune response, and interactions with infections. For the Ukrainian cystic fibrosis community, it is extremely important to remain part of these global scientific developments so that the latest knowledge, diagnostic tools, and treatment options become accessible to our patients.

We will continue working to ensure that Ukrainian patients with cystic fibrosis receive care that meets the highest international standards.